WO2004077007A2 - Detection, quantification et composition pour le cytochrome c libere depuis la mitochondrie - Google Patents
Detection, quantification et composition pour le cytochrome c libere depuis la mitochondrie Download PDFInfo
- Publication number
- WO2004077007A2 WO2004077007A2 PCT/BR2004/000022 BR2004000022W WO2004077007A2 WO 2004077007 A2 WO2004077007 A2 WO 2004077007A2 BR 2004000022 W BR2004000022 W BR 2004000022W WO 2004077007 A2 WO2004077007 A2 WO 2004077007A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cytochrome
- released
- mitochondria
- composition
- fluorescence
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/80—Cytochromes
Definitions
- the present invention refers to a method to quantify mitochondrial cytochrome c release during cellular death comprising selective permeabilization of the plasma membrane and cytochrome c immunodetection.
- Apoproteic cytochrome c is a component of the mitochondrial respiratory chain found on the external side of the inner mitochondrial membrane, which is released from the mitochondria to the cytosol after the triggering of the apoptosis process in various kinds of cell in response to various cell aggressions. Once the cytochrome c is released, along with cytosolic factors, it activates a cascade of proteases, termed caspases, which promote cell death. Given the fact that the mitochondrial release of cytochrome c is a critic step in the apoptosis process, its quantification may be used to characterize this type of cellular death.
- the known methods to measure the release of cytochrome c comprise Western blot and fluorescence microscopy.
- the Western blot technique requires the fractioning and separation of mitochondria from homogenized cell. After this stage the fractions undergo long and laborious procedures, including electrophoresis of the proteins through a gel and from this gel to a membrane, membrane incubation with primary and secondary antibodies to detect cytochrome c . Finally the cytochrome c is developed and quantified to indicate the degree of cell death. This procedure usually requires at least two days. Furthermore, during the cell homogenization, the mitochondria may break and the Western blot technique could lead to a super estimation of the cytochrome c release.
- Fluorescence microscopy is both faster and easier than the mentioned technique, but the analysis of apoptotic cells under the microscope may also be long and, more relevant, the sampling is always the main concern whenever this technique is used.
- the method described according to the present invention remarkably reduces the amount of time spent in establishing cytochrome c mitochondrial release, from at least two days to one day, while it enhances the precision on measuring and the number of analyzed cells during apoptosis.
- it is possible to perform the analysis using any method among fluorescence, chemo luminescence, calorimetric and cytometric .
- Our method is based on the differences between the lipids that make up the plasma membrane and the mitochondrial membrane. The cholesterol/phospholipid ratio is very high on the plasma membrane, whereas either the mitochondrial inner and outer membrane ratios are low because they have very little or even no cholesterol at all .
- digitonin cholesterol-specific detergents
- the present invention comprises a method to quantify the mitochondrial cytochrome c release during cell death comprising the following steps: a) selective permeabilization of the plasma membrane; b) cytochrome c immunodetection.
- the step of selective permeabilization of the plasma membrane precedes the cytochrome c immunodetection and analysis by fluorescence, chemo luminescence and chromatometry techniques .
- the invention comprises a composition to detect mitochondrial cytochrome c release, which include a primary antibody against cytochrome c, a secondary antibody associated to fluorochrome, digitonin and buffers.
- the invention comprises, still, a kit for detection of the released mitochondrial cytochrome c including primary antibody against cytochrome c, secondary antibody associated to fluorochrome, digitonine and buffers.
- the invention comprises, also, the use of a composition to quantify the released mitochondrial cytochrome c during cell death including primary antibody against cytochrome c, secondary antibody associated to fluorochrome, digitonin and buffers .
- HL-60 leukemic cells treated with Staurosporine, a protein kinase C inhibitor were used as model for apoptosis induction. These cells undergo apoptosis, quantified by the external!zation of phosphatidylserine via anexin V-FITC, when maintained in culture medium for 18 hours in the presence of the drug. Apoptosis is observed during the first 6 hours of exposure to the drug, although apoptotic signals have already been triggered inside the cells.
- Figures 1 to 9 illustrate the fluorescence histograms of cells labeled with antibody against cytochrome c analyzed by flow cytometry.
- the histograms illustrate the time-dependent decrease of HL-60 cells fluorescence exposed to Staurosporine as a consequence of cytochrome c release.
- the cells treated with Staurosporine for 1 to 6 hours and permeabilized with digitonin presented progressively lower fluorescence levels up to near the background fluorescence, as indicated by the fluorescence average (FM) , inside each histogram ( Figures 4 to 9) , suggesting that after 6 hours all cytochrome c has been released from the mitochondria.
- Experimental control exhibit untreated cells permeabilized or not with digitonin ( Figure 4 and Figure 3, respectively) . Both presented similar levels of high fluorescence, indicating that the low digitonin concentrations used did not release a significant amount of cytochrome c from the mitochondria.
- unlabeled cells Figure 1 or cells labeled only with secondary antibodies ( Figure 2) presented fluorescence on background levels .
- the HL-60 cells were incubated, or not, with 1 ⁇ M Staurosporine for 6 hours in a RPMI medium supplemented by 10% FBS, 2 mM L-glutamine, in an atmosphere of 5% C0 2 at 37°C.
- 10 6 cells were collected and washed twice with phosphate buffered saline solution (PBS) and centrifuged at 1000 g during 5 min.
- PBS phosphate buffered saline solution
- the cells were once again suspended in a 100 ⁇ l PBS solution supplemented with a mix of protease inhibitors at 1% plus 1 mM PMSF.
- the cells were vigorously shacked for 30 seconds with 0.005% digitonine.
- the volume was rectified with PBS to 10 ml, centrifuged at 5000 g for 5 min and the pellets fixated with a 2% paraformaldehyde for 20 min. After two washings in PBS under identical conditions, the cells were washed in labeling medium containing PBS, 2% fetal calf serum, 0.5% Triton X-100, 0.2% sodium azide and centrifuged at
- Figure 1 presents the result of the background fluorescence for untreated HL-60 cells.
- Figure 2 is the background fluorescence for the secondary antibody (2° Ab) of untreated cells.
- Figure 3 is the maximum fluorescence for untreated cells not permeabilized and incubated with primary (1° Ab) and secondary antibody.
- Figure 4 exhibits the maximum fluorescence of untreated cells after the permeabilization of the cells with digitonin and incubation with both antibodies.
- Figures 5 to 9 illustrate the reduction of fluorescence on HL-60 cells treated with Staurosporine incubated with both antibodies .
- the average fluorescence means the average value of the fluorescence in the region where the fluorescence is highest.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
La présente invention a trait à un procédé pour la quantification de cytochrome c libéré à partir de la mitochondrie lors de mort cellulaire comprenant la perméabilisation sélective de la membrane plasmique et l'immunodétection de cytochrome c. La présente invention a également trait à une composition pour la détection de cytochrome c libéré de la mitochondrie, à une trousse pour la détection de cytochrome c libéré depuis la mitochondrie, ainsi qu'à l'utilisation de la composition pour la détection de cytochrome c libéré depuis la mitochondrie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0300660A BRPI0300660B8 (pt) | 2003-02-28 | 2003-02-28 | método para quantificar liberação mitocondrial de citocromo c e kit para detectar liberação mitocondrial de citocromo c |
BRPI0300660-3 | 2003-02-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004077007A2 true WO2004077007A2 (fr) | 2004-09-10 |
WO2004077007A3 WO2004077007A3 (fr) | 2004-10-14 |
Family
ID=28679778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2004/000022 WO2004077007A2 (fr) | 2003-02-28 | 2004-02-26 | Detection, quantification et composition pour le cytochrome c libere depuis la mitochondrie |
Country Status (2)
Country | Link |
---|---|
BR (1) | BRPI0300660B8 (fr) |
WO (1) | WO2004077007A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10752594B2 (en) | 2013-03-14 | 2020-08-25 | Sumitomo Dainippon Pharma Oncology, Inc. | JAK1 and ALK2 inhibitors and methods for their use |
US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
-
2003
- 2003-02-28 BR BRPI0300660A patent/BRPI0300660B8/pt not_active IP Right Cessation
-
2004
- 2004-02-26 WO PCT/BR2004/000022 patent/WO2004077007A2/fr active Application Filing
Non-Patent Citations (4)
Title |
---|
CASTEDO M. ET AL.: 'Quantitation of mitochondrial alternations associated with apoptosis' J. IMMUNOL. METHODS vol. 265, no. 1-2, 2002, pages 39 - 47, XP004366298 * |
DUAN S. ET AL.: 'Mitochondrial outer membrane permeability change and hypersensitivity to digitonin early in staurosporine-induced apoptosis' J. BIOL. CHEM. vol. 278, no. 2, 2003, pages 1346 - 1353, XP002904393 * |
GOTTLIEB R.A., GRANVILLE D.J.: 'Analyzing mitochondrial changes during apoptosis' METHODS vol. 26, no. 4, 2002, pages 341 - 347, XP002904394 * |
HAJEK P. ET AL.: 'Rate-limiting step preceding cytochrome c release in cell primed fror Fas-mediated apoptosis revealed by analysis of cellular mosaicism of respiratory changes' J. BIOL. CHEM. vol. 276, no. 1, 2001, pages 606 - 615, XP002904392 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10752594B2 (en) | 2013-03-14 | 2020-08-25 | Sumitomo Dainippon Pharma Oncology, Inc. | JAK1 and ALK2 inhibitors and methods for their use |
US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
Also Published As
Publication number | Publication date |
---|---|
WO2004077007A3 (fr) | 2004-10-14 |
BRPI0300660B8 (pt) | 2021-07-27 |
BRPI0300660B1 (pt) | 2017-02-21 |
BR0300660A (pt) | 2003-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Isolation, purification and in vitro differentiation of cytotrophoblast cells from human term placenta | |
Orozco et al. | Flow cytometric analysis of circulating microparticles in plasma | |
Marchetti et al. | Study of mitochondrial membrane potential, reactive oxygen species, DNA fragmentation and cell viability by flow cytometry in human sperm | |
Liu et al. | Sex differences in caspase activation after stroke | |
Antonelou et al. | Red blood cell aging markers during storage in citrate‐phosphate‐dextrose–saline‐adenine‐glucose‐mannitol | |
Lamontagne-Proulx et al. | Portrait of blood-derived extracellular vesicles in patients with Parkinson’s disease | |
Bustamante et al. | Oxygen metabolism in human placenta mitochondria | |
Corrotte et al. | Approaches for plasma membrane wounding and assessment of lysosome-mediated repair responses | |
Mayorga-Torres et al. | Can a short term of repeated ejaculations affect seminal parameters? | |
Lalumiere et al. | Cholesteryl sulfate and sterol sulfatase in the human reproductive tract | |
CA2713196A1 (fr) | Nouveau procede de mesure et de caracterisation de microvesicules dans des liquides organiques humain | |
Grunewald et al. | Increased sperm chromatin decondensation in selected nonapoptotic spermatozoa of patients with male infertility | |
Duan et al. | Role of extracellular vesicles in release of protein adducts after acetaminophen-induced liver injury in mice and humans | |
Pozarowski et al. | NF‐κB inhibitor sesquiterpene parthenolide induces concurrently atypical apoptosis and cell necrosis: Difficulties in identification of dead cells in such cultures | |
Calenic et al. | Oral malodorous compound triggers mitochondrial‐dependent apoptosis and causes genomic DNA damage in human gingival epithelial cells | |
Han et al. | Effects of estrogenic compounds on immunoglobulin production by mouse splenocytes | |
Xiao et al. | Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells | |
Gylys et al. | Quantitative characterization of crude synaptosomal fraction (P‐2) components by flow cytometry | |
Stenqvist et al. | An efficient optimized method for isolation of villous trophoblast cells from human early pregnancy placenta suitable for functional and molecular studies | |
Gylys et al. | Enrichment of presynaptic and postsynaptic markers by size‐based gating analysis of synaptosome preparations from rat and human cortex | |
Gopinath et al. | A novel approach to study markers of dopamine signaling in peripheral immune cells | |
Li et al. | Incidence and outcome of antiglomerular basement membrane disease in Chinese | |
Das et al. | Differential toxicological endpoints of di (2-ethylhexyl) phthalate (DEHP) exposure in MCF-7 and MDA-MB-231 cell lines: Possible estrogen receptor α (ERα) independent modulations | |
Lok et al. | Microparticles of pregnant women and preeclamptic patients activate endothelial cells in the presence of monocytes | |
Alok et al. | Glycodelin A, an immunomodulatory protein in the endometrium, inhibits proliferation and induces apoptosis in monocytic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |